New Clinical Site Added

Ophthalmic Sciences has initiated recruitment at Assuta Hashalom, the country’s busiest eye clinic, also marking the testing initiation of its most advanced prototype

Company Presenting at the 2022 Glaucoma 360 Event

Ophthalmic Sciences is presenting its technology and early clinical results on February 11, 2022 at the Glaucoma 360 event. Read more

Ophthalmic Sciences Secures $1.1M Financing

Signaling a vote of confidence in the company, a $1.1M subscription has been secured from existing and new investors that will help boost R&D activities. The financing is a prelude to a $2.5M post-seed round planned to close by late Q1/2022.

Leading ophthalmologist joins company as Board member

Prof. David Goldblum, MD, a renowned researcher and industry expert joins the board, bringing much value as the company enters clinical and commercial phases. Read more

IOPerfect™ clinical study gets thumbs up, recruiting starts next week

A leading hospital in Israel, Assuta Medical Center, will host the pilot study of the IOPerfect™, to include up to 400 eyes, a key company milestone. Read more